Tuesday, March 10, 2026
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Automotive & E-Mobility

Amprius Technologies Achieves Key Profitability Milestone in Q4

Rodolfo Hanigan by Rodolfo Hanigan
March 6, 2026
in Automotive & E-Mobility, Earnings, Nasdaq, Tech & Software, Turnaround
0
Amprius Stock
0
SHARES
6
VIEWS
Share on FacebookShare on Twitter

Amprius Technologies has reported a significant operational breakthrough, achieving a positive adjusted EBITDA for the first time in a single quarter. This milestone caps a fiscal year 2025 characterized by dramatic revenue growth and a strategic pivot that sets the stage for the coming year.

Financial Performance: A Year of Dramatic Improvement

The company’s full-year revenue surged by 202% to reach $73 million. The fourth quarter was particularly strong, with sales climbing 137% year-over-year to $25.2 million. A key indicator of operational health, the gross margin, swung decisively from negative 21% in the prior year to a positive 24%.

On an adjusted basis, EBITDA for Q4 2025 was $1.8 million, a substantial improvement from a loss of $4.8 million in the same period last year. The reported net loss of $24.4 million for the quarter is primarily attributed to a one-time, non-cash impairment charge of $22.5 million related to the closure of its Colorado facility. Excluding this special item, the adjusted net loss was $1.9 million, or $0.01 per share. The company ended the year with a solid cash position of $91.9 million.

Should investors sell immediately? Or is it worth buying Amprius?

Strategic Growth and Defense Sector Expansion

Operationally, Amprius has expanded its customer base to over 550. Strategic developments include new contracts with Nokia Drone Networks and a $2.8 million increase to an existing agreement with the Defense Innovation Unit (DIU), bringing its total value to $14.8 million. A collaboration with a U.S.-based manufacturing partner to produce NDAA-compliant battery cells marks a direct move to capture business from the U.S. defense sector.

Guidance for Fiscal 2026

Looking ahead, management has provided an optimistic outlook for fiscal 2026. The company forecasts revenue of at least $125 million, representing growth of approximately 70%. Adjusted EBITDA is projected to rise to a minimum of $4 million, while the net loss for the full year is expected to be contained below $8 million. The strategic focus will remain on scaling production capacity for high-energy-density battery solutions targeting the aviation and drone industries.

Ad

Amprius Stock: Buy or Sell?! New Amprius Analysis from March 10 delivers the answer:

The latest Amprius figures speak for themselves: Urgent action needed for Amprius investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from March 10.

Amprius: Buy or sell? Read more here...

Tags: Amprius
Rodolfo Hanigan

Rodolfo Hanigan

Related Posts

The Trade Desk Stock
AI & Quantum Computing

The Trade Desk Seeks Growth Through AI Advertising Partnerships

March 10, 2026
Alibaba Stock
AI & Quantum Computing

Alibaba’s AI Overhaul Gains Momentum Amid Leadership Shifts

March 10, 2026
Coeur Mining Stock
Commodities

Coeur Mining Shares Defy Strong Fundamentals Amid Market Turbulence

March 10, 2026
Next Post
Berkshire Stock

Berkshire Hathaway Resumes Share Buyback Program After Extended Hiatus

C3.ai Stock

C3.ai Navigates a Pivotal Shift: Government Contracts Surge as Workforce Shrinks

Invesco Dynamic Pharmaceuticals ETF Stock

A Quantitative Approach to Pharmaceutical Investing: Inside the Invesco ETF's Rebalance

Recommended

Assembly Biosciences Stock

Clinical Breakthroughs and Financial Risks: Assembly Biosciences at a Crossroads

4 months ago
Robinhood Stock

Insider Selling Tests Robinhood’s Impressive Rally

5 months ago
MicroStrategy Stock

Strategy’s Dual Focus Faces Market Scrutiny as Bitcoin Bet Weighs on Shares

5 months ago
Retail Stock Bull Market

Short Interest Analysis Five Below vs Peers

2 years ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Newsletter
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple ASML BioNTech Bitcoin Bloom Energy Broadcom Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials MSCI World ETF Newmont Mining NIO Novo Nordisk Nvidia Ocugen Opendoor Oracle Palantir PayPal Plug Power QuantumScape Robinhood Rocket Lab USA Salesforce Strategy Synopsys Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics
No Result
View All Result

Highlights

Coeur Mining Shares Defy Strong Fundamentals Amid Market Turbulence

Fiserv Faces Investor Scrutiny Ahead of Key Forum Appearance

Hims & Hers Stock Soars on Surprise Partnership with Pharma Giant

The Duality of D-Wave Quantum: A Tale of Financials Versus Future Bookings

Institutional Investors Show Growing Confidence in Gilead Sciences

Outlook Therapeutics: Key Catalysts on the Horizon for Investors

Trending

Eli Lilly Stock
Analysis

Eli Lilly Shares Face Margin Concerns Amid Rival’s Price Strategy

by Rodolfo Hanigan
March 10, 2026
0

The pharmaceutical sector is bracing for potential margin compression after Novo Nordisk signaled aggressive price reductions for...

The Trade Desk Stock

The Trade Desk Seeks Growth Through AI Advertising Partnerships

March 10, 2026
Alibaba Stock

Alibaba’s AI Overhaul Gains Momentum Amid Leadership Shifts

March 10, 2026
Coeur Mining Stock

Coeur Mining Shares Defy Strong Fundamentals Amid Market Turbulence

March 10, 2026
Fiserv Stock

Fiserv Faces Investor Scrutiny Ahead of Key Forum Appearance

March 10, 2026

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • Eli Lilly Shares Face Margin Concerns Amid Rival’s Price Strategy
  • The Trade Desk Seeks Growth Through AI Advertising Partnerships
  • Alibaba’s AI Overhaul Gains Momentum Amid Leadership Shifts

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com